SCHEMBL2993978

SCHEMBL2993978

CCOC(=O)C(C)(C)CCCCCCCCCl

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.71
CYP4A11 Q02928 3/20 0.71
HTT P42858 1/20 0.46
PKM P14618 3/20 0.43
THRB P10828 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPT P10636 1/20 0.42
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PPARA Q07869 2/20 0.36
TSHR P16473 2/20 0.36
ABCB11 O95342 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
HTR2A P28223 1/20 0.36
PMP22 Q01453 1/20 0.36
ELANE P08246 1/20 0.35
ACLY P53396 1/20 0.35
ACACB O00763 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22819335 1.00 CYP4F2 (0.71) CYP4F2CYP4A11HTTPKMTHRB
SCHEMBL28404067 0.98 CYP4F2 (0.68) CYP4F2CYP4A11HTTPKMTHRB
SCHEMBL6268325 0.92 CYP4F2 (0.65) CYP4F2CYP4A11HTTPKMTHRB
SCHEMBL6254544 0.90 CYP4F2 (0.85) CYP4F2CYP4A11HTTPKMTHRB
SCHEMBL6257314 0.90 CYP4F2 (0.85) CYP4F2CYP4A11HTTPKMTHRB
SCHEMBL2983798 0.90 CYP4F2 (0.58) CYP4F2CYP4A11HTTPKMTHRB
SCHEMBL21060863 0.85 CYP4F2 (0.76) CYP4F2CYP4A11HTTPKMTHRB
SCHEMBL22748706 0.85 CYP4F2 (0.76) CYP4F2CYP4A11HTTPKMTHRB
SCHEMBL2720899 0.85 CYP4F2 (0.76) CYP4F2CYP4A11HTTPKMTHRB
SCHEMBL8249184 0.85 CYP4F2 (0.76) CYP4F2CYP4A11HTTPKMTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7777071-B2 Production of carnitine conjugate intermediates SSV THERAPEUTICS, INC. (US) 2010-08-17 US disclosed
US-20090012160-A1 Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof SSV THERAPEUTICS, INC. 2009-01-08 US disclosed
WO-2008018877-A1 CARNITINE CONJUGATES AS DUAL PRODRUGS, METHODS OF PRODUCTION AND USES THEREOF SSV THERAPEUTICS, INC. (US) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012160-A1 Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof CPT1B, CRAT, CPT2 CYP4F2 102/4885CYP4A11 244/4885HTT 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.